NeoPhore Ltd is rated 3 out of 5 in the category biotechnology. Read and write reviews about NeoPhore Ltd. NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
Address
Babraham Research Campus Room 1020
Company size
1-10 employees
Headquarters
Cambridge, Cambridgeshire